All In MedTech

Device Trial Radar · NCT05064709

Assessment of CCM in HF With Higher Ejection Fraction

Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection Fraction

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Feb 3, 2022

Primary completion

Feb 1, 2029

Study completion Feb 1, 2029

Sponsor

Lead sponsor
Impulse DynamicsNot on our public-company list
Sponsor type
Industry
First posted
Oct 1, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

Conditions

  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure With Mid Range Ejection Fraction
  • Heart Failure With Moderately Reduced Ejection Fraction
  • Diastolic Heart Failure

Interventions

  • Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini SystemDevice

    The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed ON for the first 18 months (blinded phase). CCM therapy will be programmed to deliver 7 one-hour phases of CCM therapy that are distributed equally over every 24-hour period. CCM will remain on following completion of the 18-month visit.

  • OPTIMIZER™ Smart Mini SystemDevice

    The OPTIMIZER™ Smart Mini System will be implanted and CCM will be programmed OFF for the first 18 months (blinded phase). CCM will be turned on following completion of the 18-month visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 Efficacy Endpoint - Change in 6-minute walk distance (6MWD) from baseline to 6 months.Time frame: 6 months
  2. Part 1 Efficacy Endpoint - Change in the health status from baseline to 6 months as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS).Time frame: 6 months
  3. Part 1 Safety Endpoint - The incidence of Optimizer device- or procedure-related complications within the first 12 months after implantTime frame: 12 months

1 more outcomes with a free account

Locations

67 sites in 1 country. Site status is shown where the registry gives one.

  • Grandview Medical Group Research, LLC

    Birmingham, Alabama · Recruiting

  • CardioVascular Associates of Mesa

    Mesa, Arizona · Recruiting

  • Southwest Cardiovascular Associates

    Mesa, Arizona · Recruiting

64 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.